col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Publishing House: Communicable Diseases Intensive Care Association

40 Results       Page 1

  original article Journal Date Title Authors All Authors
1 [GO] Infusion & Chemotherapy 2023―Jun―16 The role of surfactant system dysfunction in the formation of dyspnea in patients with COVID-19-associated pneumonia L.I. Konopkina, O.O. Shchudro
2 [GO] Infusion & Chemotherapy 2023―Mar―29 Somatopsychic disorders in patients with community-acquired pneumonia associated with coronavirus disease (COVID-19) Т.О. Pertseva, L.I. Konopkina, Yu.V. Huba, О.О. Shchudro, N.О. Demian
3 [GO] Infusion & Chemotherapy 2023―Mar―29 Variants of the post-COVID syndrome course depending on age, gender, comorbidity and severity of COVID-19 L.D. Todoriko, O.S. Shevchenko
4 [GO] Infusion & Chemotherapy 2023―Mar―29 Surgical tactics for the treatment of subpleural and intra-pulmonary hematomas as a result of pneumonia caused by COVID-19 M.S. Opanasenko, S.M. Bilokon, B.M. Konik, O.V. Tereshkovych, S.M. Shalagay, L.I. Levanda, et al. (+5)
5 [GO] Infusion & Chemotherapy 2023―Feb―16 Туберкульоз і COVID-19: що очікувати лікарям України? Л.В. Веселовський, С.В. Зайков
6 [GO] Infusion & Chemotherapy 2022―Oct―24 Differential diagnosis of the complicated course of COVID-19 pneumonias and infectious lung destruction O.K. Yakovenko, M.I. Lynnyk, I.V. Liskina, V.I. Ignatieva, G.L. Gumeniuk, V.V. Sokolov
7 [GO] Infusion & Chemotherapy 2022―Oct―24 Antiviral activity of aminocaproic acid against SARS-CoV-2: review of the literature and results of the first experimental study J. Chiaravalli, A. Verneuil, V. Osiichuk, D. Golyshkin, O.Ya. Dziublyk, M.I. Gumeniuk, O.S. Denysov
8 [GO] Infusion & Chemotherapy 2022―May―25 Pathogenetic treatment of patients with COVID-19 at the outpatient stage M.M. Ostrovskyi, L.I. Konopkina, K.Yu. Gashynova, G.L. Gumeniuk, D.V. Dobrianskyi, O.L. Bororova
9 [GO] Infusion & Chemotherapy 2022―May―25 Clinical case of concomitant tuberculosis and COVID-19 on the background of Churg-Strauss syndrome О.М. Raznatovska, Yu.V. Myronchuk, O.S. Shalmin, A.V. Fedorec
10 [GO] Infusion & Chemotherapy 2022―May―25 Determination of dynamics and stage of development of COVID-19 pneumonia based on digital software processing of images of computed tomography of the chest O.K. Yakovenko, Ya.O. Dziublyk, M.I. Lynnyk
11 [GO] Infusion & Chemotherapy 2022―May―25 Lung lever after COVID-19: clinical-X-ray, surgical and morphological characteristics Yu.I. Feshchenko, М.S. Opanasenko, I.V. Liskina, S.M. Bilokon, O.V. Tereshkovych, B.М. Konik, et al. (+6)
12 [GO] Infusion & Chemotherapy 2022―May―25 Endothelium is the main target of coronavirus infection M.V. Bondar, M.M. Pylypenko, O.A. Loskutov
13 [GO] Infusion & Chemotherapy 2021―Dec―27 Risks of using pre-event time scale and ordinal scale measurements in COVID-19 clinical trials M.V. Yashchenko
14 [GO] Infusion & Chemotherapy 2021―Dec―27 Diagnostics of lesions of parenchymatic organs in COVID-19 with the application of digital software processing of computer tomography images М.І. Lynnyk, І.V. Liskina, М.І. Gumeniuk, V.І. Іgnatieva, G.L. Gumeniuk, V.А. Svyatnenko, et al. (+2)
15 [GO] Infusion & Chemotherapy 2021―Dec―27 Inhaled antiseptics and inhaled antiviral non-prescription drugs in the prevention of ARVI, in particular COVID-19: an epidemiological study Yu.I. Feshchenko, M.I. Gumeniuk, М.І. Lynnyk, O.Ya. Dziublyk, M.M. Kuzhko, О.V. Tereshkovych, et al. (+5)
16 [GO] Infusion & Chemotherapy 2021―Sep―30 Diagnosis of disappearing lung syndrome as a complication of non-hospital pneumonia of viral etiology (COVID-19) Y.I. Feshchenko, М.І. Lynnyk, М.І. Gumeniuk, I.A. Kalabukha, V.І. Іgnatieva, G.L. Gumeniuk, et al. (+3)
17 [GO] Infusion & Chemotherapy 2021―Sep―30 The impact of the COVID-19 pandemic on the financial sector in medicine: features of centralized state procurement of drugs and medical devices in Ukraine for the period 2018-2021 O.S. Denysov
18 [GO] Infusion & Chemotherapy 2021―Jul―11 Pathogenetic syndrome management of a patient with COVID-19 E.M. Khodosh
19 [GO] Infusion & Chemotherapy 2021―Jul―11 Neuroinvasion and neurological complications in COVID-19 O.A. Loskutov
20 [GO] Infusion & Chemotherapy 2021―Jul―11 Organoprotection in patients with COVID-19 V.K. Tashchuk
21 [GO] Infusion & Chemotherapy 2021―Jul―11 Features of infusion therapy in patients of the therapeutic profile during the COVID-19 pandemic O.A. Halushko
22 [GO] Infusion & Chemotherapy 2021―Jul―11 Tuberculosis in the context of the COVID-19 pandemic: what to expect and how to act? L.D. Todorico
23 [GO] Infusion & Chemotherapy 2021―Jul―11 2020 challenge: the potential options of COVID-19 therapy S.V. Kovalenko
24 [GO] Infusion & Chemotherapy 2021―Jul―11 The experience of management of COVID-19: focus on the pneumonia L.V. Moroz
25 [GO] Infusion & Chemotherapy 2021―Jul―11 Peculiarities of antimicrobial therapy of viral and bacterial pneumonia in patients with coronavirus disease O.M. Nesterenko
26 [GO] Infusion & Chemotherapy 2021―Jul―11 Peculiarities of care for patients with coronavirus infection. Important safety issues for health care workers A.M. Savych
27 [GO] Infusion & Chemotherapy 2021―Jul―10 Standardized protocol for ultrasound diagnosis of the lungs with COVID-19 O.M. Safonova, O.B. Dynnyk, G.L. Gumeniuk, V.A. Lukiianchuk, H.V. Linska, M.S. Brovchenko, et al. (+2)
28 [GO] Infusion & Chemotherapy 2021―Jul―10 Diagnostics of complicated course of community-acquired pneumonia of viral etiology (COVID-19) via using chest computed tomography М.І. Lynnyk, V.І. Іgnatieva, G.L. Gumeniuk, V.А. Svyatnenko, O.R. Tarasenko, O.L. Bororova
29 [GO] Infusion & Chemotherapy 2021―Jul―10 Evaluation of the treatment efficacy in the patients with viral etiology community acquired pneumonia (COVID-19) with the use of syndrome-pathogenetic small volume infusion therapy according to computer tomography data М.І. Lynnyk, V.І. Іgnatieva, G.L. Gumeniuk, O.R. Tarasenko, S.H. Opimakh, I.V. Chumak, et al. (+3)
30 [GO] Infusion & Chemotherapy 2021―Jul―09 Therapy of patients with COVID-19: clinical studies and recommendations in different countries S. V. Zaikov
31 [GO] Infusion & Chemotherapy 2020―Oct―12 Combination of the therapy of the anticoagulants and Tivortin in patients with cardiac ishemia at COVID-19 M.J. Dzhumaeva, A.I. Tabarov, Kh.T. Fayzulloev
32 [GO] Infusion & Chemotherapy 2020―Oct―12 Prospects of infusion therapy in the treatment of severe pulmonary tuberculosis in combination with COVID-19 L.D. Todoriko, M.I. Gumeniuk, I.O. Semianiv, T.A. Sprynsian, O.S. Denysov
33 [GO] Infusion & Chemotherapy 2020―Oct―12 Peculiarities of pulmonary tuberculosis in a COVID-19 pandemic L.D. Todoriko, І.О. Сем’янів
34 [GO] Infusion & Chemotherapy 2020―Oct―12 Features of infusion therapy in therapeutic patients during the COVID-19 pandemic O.A. Halushko
35 [GO] Infusion & Chemotherapy 2020―Oct―12 Role of markers of inflammation, severity and infusion therapy in COVID-19-defined pneumonia E.M. Khodosh
36 [GO] Infusion & Chemotherapy 2020―Oct―12 Peculiarities of antimicrobial therapy of viral-bacterial pneumonia in patients with coronavirus disease O.M. Nesterenko
37 [GO] Infusion & Chemotherapy 2020―Oct―10 COVID-19 and comorbid chronic diseases S. V. Zaikov
38 [GO] Infusion & Chemotherapy 2020―Oct―10 Peculiarities of tuberculosis in the COVID-19 pandemic L. D. Todoriko, I. O. Semianiv
39 [GO] Infusion & Chemotherapy 2020―Sep―11 Methods of visualization in the diagnosis of COVID-19 community-acquired pneumonia М.І. Gumeniuk, V.І. Іgnatieva, М.І. Lynnyk, G.L. Gumeniuk, V.А. Svyatnenko, M.G. Palivoda
40 [GO] Infusion & Chemotherapy 2020―Sep―11 Viral load as a marker of the risk of severe course and progression of COVID-19: a review Y. I. Feshchenko

40 Results       Page 1


Last change 2023―Apr―13 19:50:14 UTC

© Daten-Quadrat 2022       Done in 0.016 sec